Key additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product
Rotterdam, The Netherlands, 19 August 2015 – SkylineDx, a molecular diagnostics company developing and commercializing innovative gene signature based diagnostics, today announces the appointment of Leonard Kruimer as Chief Financial Officer per August 15th and Peter Schineller as Chief Commercial Officer per August 1st. Mr. Kruimer brings more than 30 years of experience in corporate finance, planning and strategy, including 15 years in senior executive positions in private and publicly listed biotechnology companies like Crucell. Mr. Schineller’s 25- year professional career spans both the diagnostic and pharmaceutical industries. Most recently, Mr. Schineller served as Chief Commercial Officer at diagnostics company Agendia of Amsterdam and Irvine, California.
Dharminder Chahal, SkylineDx’s Chief Executive Officer and founder said: “As we continue our growth momentum thru 2015 and beyond, we are committed to building a world class healthcare organization that is strategically focused on the broad expansion of our current and future signature based diagnostics portfolio. To that end, we are thrilled to add Leonard Kruimer and Peter Schineller to our executive team.”
“Mr. Kruimer’s and Schineller’s depth of experience as a senior commercial leader within the fast growing life sciences sector will enable SkylineDx to fulfill its global signature based diagnostics business objectives as we accelerate the development of our groundbreaking signature-based diagnostics and prepare for the launch of our first product.”
Leonard Kruimer, CFO
Leonard Kruimer was CFO and Management Board member of the Netherlands-based vaccine company Crucell from 1998 through to 2011, when Johnson & Johnson acquired the company. During his tenure at Crucell he was responsible for financing the company in private and public markets, including the IPO at Nasdaq and Euronext in 2000 and subsequent listing on the Swiss Stock Exchange in 2006. Mr. Kruimer was closely involved in the company’s M&A strategy, including the acquisition and integration of Swiss-based Berna Biotech. He served as the Chairman of the Supervisory Board of private biotech company ProFibrix from 2011 through to its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013. In 2014 he served as financial director of Dutch biotech company BBB Therapeutics. Prior to his time at Crucell, Leonard Kruimer was Managing Director at TIP Europe, a unit of GE Capital. He was a consultant with McKinsey & Company and started his career at Price Waterhouse in New York. Mr. Kruimer holds an MBA from the Harvard Business School and is a Certified Public Accountant in New York State.
Peter Schineller, CCO
In the CCO position, Mr. Schineller will lead SkylineDx’s global commercialization activities as it delivers technologies to translate personalized diagnostics into actionable, patient-centered solutions for clinicians. Most recently, Mr. Schineller served as Chief Commercial Officer at Dutch/American Agendia for more than two years, where he restructured the commercial organization and was instrumental in driving ongoing, positive annual growth. Prior to that he was Senior Vice President and Chief Commercial Officer at Alexza Pharmaceuticals. Other key positions held include: Senior Vice President and General Manager at Ventana Medical Systems, a Roche company and Senior Vice President Sales, Marketing and Commercial Operations, at Genoptix Medical Laboratories, acquired by Novartis. Mr. Schineller was also a co-founder at Verus pharmaceuticals and held positions of increasing responsibility in sales and marketing with Abbott Laboratories, Dura/Elan and Cypress Bioscience.
About SkylineDx
SkylineDx, based in Rotterdam, the Netherlands, is an innovative biotechnology company specializing in developing and commercializing innovative, signature-based diagnostics with a high clinical value that help to provide physicians and patients with the best individual care possible. Skyline is a spin-off of Erasmus Medical Center in Rotterdam, the Netherlands.
Shareholder
Dutch life sciences investor Van Herk Ventures is a major shareholder in the company and has been instrumental for its strong scientific development since its inception in 2013. Van Herk Ventures invests in the life sciences sector through direct investments in private and listed companies and in venture capital funds, like Devgen (acquired by Syngenta), Crucell (acquired by Johnson&Johson) and Octoplus (acquired by Dr. Reddy’s) and Venture Capital company Forbion. At present Van Herk has significant shareholdings in promising Life Sciences- en Medtech companies such as Dutch Galapagos (partnered with AbbVie), French Innate Pharma (partnered with Bristol-Myers Squibb and AstraZeneca) and Dutch diagnostics company Agendia.
About MMprofiler
In USA only available for research only www.mmprofiler.com and www.mmprofiler.nl
